Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. 4d Molecular Therapeutics

Evaluate

February 24, 2023

Spotlight – Cystic fibrosis developers take a deep breath

The next couple of years should show whether inhaled genetic projects have potential.

Thumbnail
January 10, 2023

Another Fabry flop, courtesy of 4D

Article image
Vantage logo
October 24, 2022

Syncona sets its sights on a gene therapy turnaround

But, with Applied Genetic Technologies Corporation, can lightning strike a third time?

Article image
Vantage logo
October 12, 2022

ESGCT 2022 – Sangamo strengthens its case in Fabry

The group looks like the gene therapy contender to beat, but that is not saying much.

Article image
Vantage logo
February 24, 2022

Amicus exits gene therapy

Spac backtrack confirms that the gene therapy bubble has burst

Article image
Vantage logo
February 14, 2022

Angiogenesis 2022 – Regeneron and Bayer see positive signs for long-acting Eylea

The omens look good for the upcoming Pulsar readout, but can Eylea keep its wet AMD stranglehold?

Article image
Vantage logo
November 10, 2021

Freeline’s Fabry data fall short

Article image
Vantage logo
November 04, 2021

Sangamo takes on 4D in Fabry

Article image
Vantage logo
October 26, 2021

4D gets a good start in Fabry

But a serious adverse event and waning enzyme levels raise questions about the data.

Article image
Vantage logo
October 20, 2021

Boehringer takes a different approach in cystic fibrosis gene therapy

Deals this week with a UK consortium and Oxford Biomedica see the group bet on lentiviral vectors.

Article image
Vantage logo
October 12, 2021

Idorsia’s Fabry flop puts focus on gene therapies

But questions about gene therapy safety could benefit the enzyme-replacement therapy incumbents.

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

May 15, 2023

Pharma’s Biggest Spenders 2022 Infographic

May 03, 2023

Gene Editing: Overhyped or Unstoppable Tide?

View more...

Editor's Picks

Vantage logo
May 16, 2023

Heightened US antitrust fears rattle biopharma

Vantage logo
May 11, 2023

2023’s biggest launches: the story so far

Vantage logo
May 17, 2023

Viking’s Voyage is not over yet

Vantage logo
May 09, 2023

Gene editing: overhyped or unstoppable tide?

Vantage logo
May 16, 2023

A slow (and low) year for FDA approvals

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up